Diagnosis and reversal of multidrug resistance in paediatric cancers.
作者信息
Chan H S, Grogan T M, DeBoer G, Haddad G, Gallie B L, Ling V
机构信息
Department of Pediatrics, University of Toronto, Ontario, Canada.
出版信息
Eur J Cancer. 1996 Jun;32A(6):1051-61. doi: 10.1016/0959-8049(96)00085-8.
PMID:8763347
Abstract
摘要
相似文献
1
Diagnosis and reversal of multidrug resistance in paediatric cancers.儿童癌症中多药耐药的诊断与逆转
Eur J Cancer. 1996 Jun;32A(6):1051-61. doi: 10.1016/0959-8049(96)00085-8.
2
Pharmacological considerations in the modulation of multidrug resistance.多药耐药性调控中的药理学考量
Eur J Cancer. 1996 Jun;32A(6):1082-8. doi: 10.1016/0959-8049(96)00111-6.
3
Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.急性髓系白血病及其他血液系统恶性肿瘤中多药耐药的逆转
Eur J Cancer. 1996 Jun;32A(6):1062-9. doi: 10.1016/0959-8049(96)00054-8.
4
Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.通过药理学化学增敏剂对P-糖蛋白介导的多药耐药性进行实验性逆转。
Eur J Cancer. 1996 Jun;32A(6):991-1001. doi: 10.1016/0959-8049(96)00047-0.
5
Multidrug resistance reversal in childhood malignancies--potential for a real step forward?儿童恶性肿瘤中的多药耐药逆转——真正取得进展的潜力？
Eur J Cancer. 1996 Apr;32A(4):641-4. doi: 10.1016/0959-8049(95)00663-x.
6
Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance.多药耐药相关蛋白（MRP）介导的耐药性的实验调控
Eur J Cancer. 1996 Jun;32A(6):1002-9. doi: 10.1016/0959-8049(96)00067-6.
7
Biology of the multidrug resistance-associated protein, MRP.多药耐药相关蛋白MRP的生物学特性
Eur J Cancer. 1996 Jun;32A(6):945-57. doi: 10.1016/0959-8049(96)00046-9.
8
MDR1/P-glycoprotein in haematological neoplasms.血液系统肿瘤中的多药耐药蛋白1/ P-糖蛋白
Eur J Cancer. 1996 Jun;32A(6):1034-8. doi: 10.1016/0959-8049(96)00055-x.
9
Clinical trials of P-glycoprotein reversal in solid tumours.实体瘤中P-糖蛋白逆转的临床试验。
Eur J Cancer. 1996 Jun;32A(6):1070-81. doi: 10.1016/0959-8049(96)00091-3.
10
P-glycoprotein mediated multidrug resistance and its implications for pathology.
Pathology. 1997 May;29(2):122-30. doi: 10.1080/00313029700169734.
引用本文的文献
1
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.P-糖蛋白抑制剂 tariquidar（XR9576）与阿霉素、长春瑞滨或多西他赛联合用于难治性实体瘤儿童和青少年的药代动力学和药效学研究。
Cancer Chemother Pharmacol. 2015 Dec;76(6):1273-83. doi: 10.1007/s00280-015-2845-1. Epub 2015 Oct 20.
Zotero 插件